To explore the advancements in continuous intraocular pressure (IOP) monitoring technologies and their potential impact on glaucoma management, emphasizing improvements in patient outcomes.
Key Findings:
Continuous monitoring technologies can capture diurnal and nocturnal IOP patterns, improving risk stratification in glaucoma and potentially leading to more tailored treatment approaches.
The Sensimed Triggerfish CLBS is the most studied device, correlating well with standard tonometry methods and demonstrating its clinical relevance.
Implantable bioMEMS sensors like Eyemate-IO and Eyemate-SC show promise for continuous IOP monitoring, with early studies indicating safety and accuracy, although further validation is needed.
Interpretation:
Continuous IOP monitoring technologies have the potential to enhance glaucoma management by providing comprehensive data on IOP fluctuations, which may lead to better treatment strategies and improved patient outcomes.
Limitations:
Implantable devices require surgical implantation and carry associated risks, including potential complications.
Measurement drift and calibration issues have been noted with some devices, which may affect long-term reliability.
Conclusion:
Emerging technologies in continuous IOP monitoring, including CLBS and bioMEMS, represent significant advancements in glaucoma care, offering the potential for improved patient outcomes through better monitoring and individualized treatment strategies.
